Primary sclerosing cholangitis: Overview and update

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 11, 2010, Pages 611-619

  Mendes, Flavia ^a   Lindor, Keith D ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA TUBULIN; CARDIOLIPIN ANTIBODY; CHEMOKINE; CHEMOKINE CCL25; CHEMOKINE CCL28; COLESTYRAMINE; HLA DR ANTIGEN; IMMUNOGLOBULIN G4; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; OPIATE ANTAGONIST; PLACEBO; RIFAMPICIN; SMOOTH MUSCLE ANTIBODY; STROMELYSIN; THYROID PEROXIDASE ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; AGE DISTRIBUTION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CAUSAL ATTRIBUTION; CHOLELITHIASIS; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; COMMON BILE DUCT STONE; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; INCIDENCE; JAUNDICE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALIGNANT TRANSFORMATION; METABOLIC BONE DISEASE; OVERALL SURVIVAL; PATHOGENESIS; PLASMAPHERESIS; PORTAL HYPERTENSION; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; ULCERATIVE COLITIS; VARICOSIS; VITAMIN DEFICIENCY; WEIGHT REDUCTION;

CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; COLORECTAL NEOPLASMS; HUMANS; LIVER TRANSPLANTATION; RISK FACTORS;

EID: 78049530861     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.155     Document Type: Review

References (93)

1. Bambha, K. et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125, 1364-1369 (2003).
2. Boberg, K. M. et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33, 99-103 (1998).
3. Farrant, J. M. et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100, 1710-1717 (1991).
4. Kaplan, G. G., Laupland, K. B., Butzner, D., Urbanski, S. J. & Lee, S. S. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am. J. Gastroenterol. 102, 1042-1049 (2007).
5. Kingham, J. G., Kochar, N. & Gravenor, M. B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 126, 1929-1930 (2004).
6. Wiesner, R. H. et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10, 430-436 (1989).
7. Lindkvist, B., Benito de Valle, M., Gullberg, B. & Bjornsson, E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52, 571-577 (2010).
8. Broome, U. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38, 610-615 (1996).
9. Quigley, E. M. et al. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 85, 1160-1165 (1983).
10. Bergquist, A., Lindberg, G., Saarinen, S. & Broome, U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J. Hepatol. 42, 252-256 (2005).
11. LaRusso, N. F. et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44, 746-764 (2006).
12. Norris, S. et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 120, 1475-1482 (2001).
13. Karlsen, T. H. et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138, 1102-1111 (2010).
14. Mitchell, S. A. et al. Association of the tumour necrosis factor alpha-308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 49, 288-294 (2001).
15. Bernal, W., Moloney, M., Underhill, J. & Donaldson, P. T. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J. Hepatol. 30, 237-241 (1999).
16. Satsangi, J. et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 121, 124-130 (2001).
17. Yang, X., Cullen, S. N., Li, J. H., Chapman, R. W. & Jewell, D. P. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J. Hepatol. 40, 375-379 (2004).
18. Eksteen, B., Afford, S. C., Wigmore, S. J., Holt, A. P. & Adams, D. H. Immune-mediated liver injury. Semin. Liver Dis. 27, 351-366 (2007).
19. Angulo, P. et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J. Hepatol. 32, 182-187 (2000).
20. Bansi, D. S., Fleming, K. A. & Chapman, R. W. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 38, 384-389 (1996).
21. Terjung, B. et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59, 808-816 (2010).
22. Adams, D. H. & Eksteen, B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat. Rev. Immunol. 6, 244-251 (2006).
23. Eksteen, B. et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J. Exp. Med. 200, 1511-1517 (2004).
24. Lee, Y. M. & Kaplan, M. M. Primary sclerosing cholangitis. N. Engl. J. Med. 332, 924-933 (1995).
25. Fulcher, A. S. et al. Primary sclerosing cholangitis: evaluation with MR cholangiography\a case-control study. Radiology 215, 71-80 (2000).
26. Talwalkar, J. A., Angulo, P., Johnson, C. D., Petersen, B. T. & Lindor, K. D. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 40, 39-45 (2004).
27. Textor, H. J. et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 34, 984-990 (2002).
28. Burak, K. W., Angulo, P. & Lindor, K. D. Is there a role for liver biopsy in primary sclerosing cholangitis? Am. J. Gastroenterol. 98, 1155-1158 (2003).
29. Ludwig, J. et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1, 632-640 (1981).
30. Bjornsson, E. et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134, 975-980 (2008).
31. Angulo, P., Maor-Kendler, Y. & Lindor, K. D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 35, 1494-1500 (2002).
32. Bjornsson, E. et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51, 731-735 (2002).
33. Broome, U. et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J. Hepatol. 36, 586-589 (2002).
34. Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51, 660-678 (2010).
35. Ghazale, A. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134, 706-715 (2008).
36. Bjornsson, E., Chari, S. T., Smyrk, T. C. & Lindor, K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 45, 1547-1554 (2007).
37. Mendes, F. D. et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 101, 2070-2075 (2006).
38. Song, T. J. et al. The combined measurement of total serum IgG and IgG4 may increase diagnostic sensitivity for autoimmune pancreatitis without sacrificing specificity, compared with IgG4 alone. Am. J. Gastroenterol. 105, 1655-1660 (2010).
39. Saarinen, S., Olerup, O. & Broome, U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 95, 3195-3199 (2000).
40. Silveira, M. G., Mendes, F. D., Diehl, N. N., Enders, F. T. & Lindor, K. D. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int. 29, 1094-1100 (2009).
41. Rubio-Tapia, A. & Murray, J. A. The liver in celiac disease. Hepatology 46, 1650-1658 (2007).
42. Mendes, F. D. et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am. J. Gastroenterol. 102, 344-350 (2007).
43. Schrumpf, E. et al. Sclerosing cholangitis in ulcerative colitis. Scand. J. Gastroenterol. 15, 689-697 (1980).
44. Loftus, E. V. Jr et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91-96 (2005).
45. Cangemi, J. R. et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96, 790-794 (1989).
46. Dvorchik, I. et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 35, 380-384 (2002).
47. Alabraba, E. et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 15, 330-340 (2009).
48. Moncrief, K. J. et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation\a single-centre experience. Can. J. Gastroenterol. 24, 40-46 (2010).
49. Broome, U., Lofberg, R., Veress, B. & Eriksson, L. S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22, 1404-1408 (1995).
50. Lindberg, B. U., Broome, U. & Persson, B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis. Colon Rectum 44, 77-85 (2001).
51. Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S. & Blackstone, M. O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 56, 48-54 (2002).
52. Bergquist, A. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol. 36, 321-327 (2002).
53. Burak, K. et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99, 523-526 (2004).
54. Claessen, M. M., Vleggaar, F. P., Tytgat, K. M., Siersema, P. D. & van Buuren, H. R. High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol. 50, 158-164 (2009).
55. Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C. & Lindor, K. D. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48, 1106-1117 (2008).
56. Levy, C. et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50, 1734-1740 (2005).
57. Chalasani, N. et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31, 7-11 (2000).
58. Siqueira, E. et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest. Endosc. 56, 40-47 (2002).
59. Heimbach, J. K. et al. Transplantation for hilar cholangiocarcinoma. Liver Transpl. 10 (10 Suppl. 2), S65-S68 (2004).
60. Rea, D. J. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242, 451-458 (2005).
61. Buckles, D. C., Lindor, K. D., Larusso, N. F., Petrovic, L. M. & Gores, G. J. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol. 97, 1138-1142 (2002).
62. Lewis, J. T., Talwalkar, J. A., Rosen, C. B., Smyrk, T. C. & Abraham, S. C. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am. J. Surg. Pathol. 31, 907-913 (2007).
63. Said, K., Glaumann, H. & Bergquist, A. Gallbladder disease in patients with primary sclerosing cholangitis. J. Hepatol. 48, 598-605 (2008).
64. Hay, J. E. et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14, 257-261 (1991).
65. Angulo, P. et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J. Hepatol. 29, 729-735 (1998).
66. Campbell, M. S., Lichtenstein, G. R., Rhim, A. D., Pazianas, M. & Faust, T. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int. 25, 311-316 (2005).
67. Zein, C. O. et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42, 762-771 (2005)
68. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51, 237-267 (2009).
69. Jorgensen, R. A., Lindor, K. D., Sartin, J. S., LaRusso, N. F. & Wiesner, R. H. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J. Clin. Gastroenterol. 20, 215-219 (1995).
70. Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology 50, 291-308 (2009).
71. Abraham, S. C., Kamath, P. S., Eghtesad, B., Demetris, A. J. & Krasinskas, A. M. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am. J. Surg. Pathol. 30, 1454-1461 (2006).
72. Zein, C. O., Lindor, K. D. & Angulo, P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 39, 204-210 (2004).
73. Wiesner, R. H., LaRusso, N. F., Dozois, R. R. & Beaver, S. J. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 90, 316-322 (1986).
74. Lindor, K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336, 691-695 (1997).
75. Olsson, R. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129, 1464-1472 (2005).
76. Lindor, K. D. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50, 808-814 (2009).
77. Pardi, D. S., Loftus, E. V. Jr, Kremers, W. K., Keach, J. & Lindor, K. D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124, 889-893 (2003).
78. Tung, B. Y. et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med. 134, 89-95 (2001).
79. Baluyut, A. R., Sherman, S., Lehman, G. A., Hoen, H. & Chalasani, N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest. Endosc. 53, 308-312 (2001).
80. Gluck, M. et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J. Clin. Gastroenterol. 42, 1032-1039 (2008).
81. Stiehl, A., Rudolph, G., Kloters-Plachky, P., Sauer, P. & Walker, S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J. Hepatol. 36, 151-156 (2002).
82. Kaya, M. et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am. J. Gastroenterol. 96, 1059-1066 (2001).
83. Ahrendt, S. A. et al. Primary sclerosing cholangitis: resect, dilate, or transplant? Ann. Surg. 227, 412-423 (1998).
84. Graziadei, I. W. et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30, 1121-1127 (1999).
85. Wiesner, R. H. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract. Res. Clin. Gastroenterol. 15, 667-680 (2001).
86. Welsh, F. K. & Wigmore, S. J. Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation 77, 602-604 (2004).
87. Brandsaeter, B. et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl. 9, 961-969 (2003).
88. Graziadei, I. W. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29, 1050-1056 (1999).
89. Boberg, K. M. et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 35, 652-657 (2002).
90. Dickson, E. R. et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103, 1893-1901 (1992).
91. Kim, W. R. et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75, 688-694 (2000).
92. Shetty, K., Rybicki, L. & Carey, W. D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 25, 1049-1053 (1997).
93. Mendes, F. D., Kim, W. R., Pedersen, R., Therneau, T. & Lindor, K. D. Mortality attributable to cholestatic liver disease in the United States. Hepatology 47, 1241-1247 (2008).